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1. INTRODUCTION {#mgg3942-sec-0005}
===============

Hypertension is the main factor for morbidity and mortality worldwide (Kearney et al., [2005](#mgg3942-bib-0009){ref-type="ref"}; Staessen, Wang, Bianchi, & Birkenhager, [2003](#mgg3942-bib-0026){ref-type="ref"}; Stokes, Kannel, Wolf, D\'Agostino, & Cupples, [1989](#mgg3942-bib-0027){ref-type="ref"}). However, the specific pathogenesis of hypertension is still unclear. (Mein, Caulfield, Dobson, & Munroe, [2004](#mgg3942-bib-0017){ref-type="ref"}). Several studies have shown that the etiology and pathogenesis of hypertension are likely to comprise a multifactorial disorder resulting from environmental factors (overweight, alcohol, and smoke) and genetic factors or their interaction (Carretero & Oparil, [2000](#mgg3942-bib-0003){ref-type="ref"}; Lu et al., [2015](#mgg3942-bib-0015){ref-type="ref"}). Recently, hypertension has been found to be the main factor in the occurrence of myocardial infarction, stroke, cardiac and renal failure and later lesions of the retina of the eyes (Mosterd et al., [1999](#mgg3942-bib-0019){ref-type="ref"}), and that has also been steadily increasing in China for the past several years.

Hypertension can reduce the function of which is easy to form atherosclerosis (Fujimaki et al., [2015](#mgg3942-bib-0005){ref-type="ref"}), and atherosclerosis is the main pathological basis of coronary heart disease (Lefevre & Puymirat, [2017](#mgg3942-bib-0011){ref-type="ref"}; Savoia et al., [2017](#mgg3942-bib-0022){ref-type="ref"}). *SMARCA4* (OMIM: 603254) and *ZC3HC1* (OMIM: 603254) are high‐risk genes for coronary heart disease. At present, there are many researches about the association between *SMARCA4* and *ZC3HC1* and coronary heart disease. For examples, GWAS study showed that *SMARCA4* was related to coronary heart disease (Kathiresan, Voight, et al., [2009](#mgg3942-bib-0007){ref-type="ref"}) and myocardial infarction (Martinelli et al., [2010](#mgg3942-bib-0016){ref-type="ref"}). Previous studies were also identified rs11879293, rs12232780, rs2072382, and rs1529729 variants\' effect on hypertension and dyslipidemia‐related disease (Fujimaki et al., [2015](#mgg3942-bib-0005){ref-type="ref"}; Liu et al., [2011](#mgg3942-bib-0014){ref-type="ref"}). Guo et al. ([2017](#mgg3942-bib-0006){ref-type="ref"}) found the variant in the *SMARCA4* was associated with coronary heart disease susceptibility in Han Chinese population. Linseman et al. ([2017](#mgg3942-bib-0013){ref-type="ref"}) identified that *ZC3HC1* was associated with protection from coronary artery disease. However, few studies have examined the association between *SMARCA4* and *ZC3HC1* and hypertension risk. For the current study, we evaluated the association between eight SNPs in *SMARCA4* and *ZC3HC1* and hypertension risk, and aimed to find the relations of these SNPs and hypertension risk in Han Chinese population.

2. MATERIALS AND METHODS {#mgg3942-sec-0006}
========================

2.1. Ethics statement {#mgg3942-sec-0007}
---------------------

This investigation was conducted in accordance with the ethical standards of the Declaration of Helsinki and following the national and international guidelines. Additionally, the protocol of this study was approved by the ethics committee of the first affiliated Hospital of Xi\'an Jiaotong University. Written informed consent was obtained from all the participants after a full explanation of the study. The experimental protocol was implemented in accordance with the approved guidelines.

2.2. Subjects {#mgg3942-sec-0008}
-------------

We recruited a total of 350 patients, which were diagnosed with hypertension, and were enrolled from Northwestern China at the first affiliated Hospital of Xi\'an Jiaotong University. The controls were 483 healthy subjects recruited from routine healthy examinations in the same hospital. All subjects were from the Chinese Han population living in Shaanxi province. Hypertensive subjects were defined as having a systolic blood pressure (SBP) of at least 140 mmHg and a diastolic blood pressure (DBP) of at least 90 mmHg (de Menezes, Oliveira, & Ma, [2014](#mgg3942-bib-0004){ref-type="ref"}). All the hypertensive patients were not only required to be free of other cardiovascular diseases, metabolic diseases, cancers or familial hereditary disease, but diagnosed with hypertension before the age of 70 years. Normotensive controls were recruited from the same hospital. These individuals were never treated with antihypertensive medications, and their SBP were less than 140 mmHg and DBP less than 90 mmHg. They had no family history of hypertension.

2.3. SNP selection and genotyping {#mgg3942-sec-0009}
---------------------------------

Eight SNPs in *ZC3HC1* and *SMARCA4* had minor allele frequencies greater than 5% in the 1000 Genomes Project (<http://www.internationalgenome.org/>). A GoldMag‐Mini Purification Kit (GoldMag Co. Ltd.) was performed to extract genomic DNA from whole blood. DNAs were stored at −80°C until analysis. DNA concentrations were measured using a NanoDrop 2000 (Thermo Scientific). The primers were designed online (<https://agenacx.com/online-tools/>). Agena MassARRAY Assay Design 4.0 software was used to design multiplexed SNP MassEXTEND assay, and SNP genotyping was performed utilizing the Agena MassARRAY RS1000 as recommended by the manufacturer. Agena Typer 4.0 software was used to perform data management and analyses.

2.4. Statistical analysis {#mgg3942-sec-0010}
-------------------------

All statistical analyses were performed using Microsoft Excel and SPSS 19.0 (SPSS). All *p* values were two‐sided (*p* *\< *.05 was considered as achieving the threshold of statistical significance). Each SNP frequency in the control subjects was tested by deviation from Hardy--Weinberg equilibrium by the Fisher\'s test. Allele frequencies and genotype frequencies for each SNP in cases and controls were compared by the chi‐squared test/Fisher\'s exact test to determine the associations between genotypes and hypertension risk. Odds ratio (OR) values and 95% confidence intervals (CIs) measured the risk allele effect size using unconditional logistic regression analysis (Bland & Altman, [2000](#mgg3942-bib-0002){ref-type="ref"}). Four genetic models (codominant, dominant, recessive, and log‐additive) were used to evaluate the potential association of *ZC3HC1* and *SMARCA4* polymorphisms with risk and clinical parameters of hypertension. Finally, the Haploview was used to construct haplotype and genetic association at significant polymorphism loci and to estimate the pairwise linkage disequilibrium (LD), haplotype software (version4.2) and SHEsis software platform (<http://www.nhgg.org/analysis/>) ction, and genetic association at polymorphism loci (Barrett, Fry, Maller, & Daly, [2005](#mgg3942-bib-0001){ref-type="ref"}; Shi & He, [2005](#mgg3942-bib-0024){ref-type="ref"}). Power and Sample Size Calculation software (<http://biostat.mc.vanderbilt.edu/wiki/Main/PowerSampleSize>) was used to calculate the power of the significant difference.

3. RESULTS {#mgg3942-sec-0011}
==========

3.1. Characteristics of the participants {#mgg3942-sec-0012}
----------------------------------------

This study involved 889 subjects, including 350 patients (204 males and 146 females; age at diagnosis: 62.68 ± 10.7 years) and 483 healthy controls (183 males and 300 females; age: 50.37 ± 7.9 years).There were statistical differences in age and sex distribution between the case and control groups (Table [1](#mgg3942-tbl-0001){ref-type="table"}).

###### 

General characteristics of the study population

  variable                Cases (*n* = 350)   \%     Controls (*n* = 483)   \%     *p* value
  ----------------------- ------------------- ------ ---------------------- ------ ----------------------------------------------
  Gender                                                                           \<.001[a](#mgg3942-note-0002){ref-type="fn"}
  Male                    204                 58.3   183                    37.9    
  Female                  146                 41.7   300                    62.1    
  Age, yr (mean ± *SD*)   62.68 ± 10.7               50.37 ± 7.9                   \<.01[b](#mgg3942-note-0003){ref-type="fn"}

^a^ *p* values were calculated by Student\'s *t* tests.

^b^ *p* values were calculated from two‐sided chi‐squared tests.
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3.2. The associations between ZC3HC1 and SMARCA4 SNPs and hypertension {#mgg3942-sec-0013}
----------------------------------------------------------------------

Eight SNPs in *ZC3HC1* and *SMARCA4* were selected. Position, alleles, and minor allele frequency of these SNPs were showed in Table [2](#mgg3942-tbl-0002){ref-type="table"}. One SNP (rs2072382) was excluded for significant deviation from Hardy--Weinberg equilibrium (*p* \< .05), a chi‐square analysis revealed that no significant differences in allele frequency distributions of SNPs between the hypertension patients group and the healthy control analyzed. In other words, there is no statistically significant association between allele and hypertension risk.

###### 

Allele frequencies in cases and controls and odds ratio estimates for hypertension risk

  SNP          Gene(s)     Locus     Alleles (A/B)   MAF     *p* values   OR (95%CI)                                          *p* [a](#mgg3942-note-0005){ref-type="fn"} value   *p* [b](#mgg3942-note-0005){ref-type="fn"} value   
  ------------ ----------- --------- --------------- ------- ------------ --------------------------------------------------- -------------------------------------------------- -------------------------------------------------- ------
  rs2242487    *ZC3HC1*    7q32.2    A/G             0.233   0.270        0.249                                               0.82 (0.66--1.03)                                  .088                                               .011
  rs1464890    *ZC3HC1*    7q32.2    T/C             0.277   0.314        0.247                                               0.94 (0.68--1.04)                                  .102                                               .013
  rs4507692    *ZC3HC1*    7q32.2    T/C             0.277   0.314        0.246                                               0.84 (0.68--1.04)                                  .108                                               .014
  rs11879293   *SMARCA4*   19p13.2   A/G             0.237   0.259        0.097                                               0.89 (0.71--1.12)                                  .313                                               .039
  rs12232780   *SMARCA4*   19p13.2   A/G             0.199   0.213        0.135                                               0.91 (0.72--1.16)                                  .466                                               .058
  rs2072382    *SMARCA4*   19p13.2   T/C             0.337   0.280        **0.018** [\#](#mgg3942-note-0005){ref-type="fn"}   1.31 (1.06--1.62)                                  .012                                               .002
  rs1529729    *SMARCA4*   19p13.2   C/T             0.224   0.228        0.091                                               0.98 (0.78--1.24)                                  .871                                               .109
  rs1122608    *SMARCA4*   19p13.2   T/G             0.066   0.084        0.561                                               0.77 (0.53--1.12)                                  .169                                               .021

Abbreviations: Alleles A/B, Minor/major alleles; CI, confidence interval; HWE, Hardy--Weinberg equilibrium; MAF, minor allele frequency; OR, odds ratio; SNP, single‐nucleotide polymorphism.

^\#^Site with HWE *p* ≤ .05 excluded; ^a^ *p* values were calculated using two‐sided chi‐squared test. ^b^ *p* values were adjusted by Bonferroni correction. ^a^ *p* \< .05 indicates statistical significance; ^b^ *p* \< .05 indicates statistical significance.
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3.3. Associations between genotype frequencies and hypertension risk {#mgg3942-sec-0014}
--------------------------------------------------------------------

As shown in Table [3](#mgg3942-tbl-0003){ref-type="table"}, logistic regression analyses revealed that the genotype "T/C" of rs1464890 in *ZC3HC1* was associated with a decreased risk of hypertension in the codominant model (OR = 0.48, 95% CI, 0.47--0.98, *p* = .044) and dominant model (OR = 0.65, 95% CI, 0.46--0.93, *p* = .016), respectively. Rs4507692 in *ZC3HC1* was associated with a 0.69‐fold and a 0.66‐fold decreased risk of hypertension under the codominant model and dominant model, respectively. The genotype "G/A‐A/A" of rs11879293 in *SMARCA4* was significantly associated with decreasing the risk of hypertension under the dominant model (OR = 0.70; 95% CI = 0.49--0.99, *p* = .044). Rs1122608 in *SMARCA4* was also significantly associated with a decreased risk of hypertension in the dominant model (OR = 0.61; 95% CI = 0.38--0.99, *p* = .047 for the "G/T‐T/T" genotype) and log‐additive model (OR = 0.61; 95% CI = 0.38--0.98, *p* = .038), respectively. Furthermore, the statistical power of our study was more than 80%.

###### 

Relationships between *ZC3HC1* and *SMARCA4* polymorphism and hypertension risk

  SNP            Model        Genotype     Genotype frequency   *p* [a](#mgg3942-note-0008){ref-type="fn"}‐value   OR (95% CI)             Study power   
  -------------- ------------ ------------ -------------------- -------------------------------------------------- ----------------------- ------------- ----------
  *ZC3HC1*                                                                                                                                               
  rs2242487      Codominant   G/G          262 (54.4            209 (59.7)                                         .158                    1              
  A/G            180 (37.3)   119 (34.0)                        0.71 (0.49--1.03)                                                                        
  A/A            40 (8.3)     22 (6.3)                          0.69 (0.35--1.38)                                                                        
  Dominant       G/G          262 (54.4)   209 (59.7)           .054                                               1                                     
  A/G‐A/A        220 (45.6)   141 (40.3)                        0.71 (0.50--1.01)                                                                        
  Recessive      G/G‐A/G      442 (91.7)   328 (93.7)           .479                                               1                                     
  A/A            40 (8.3)     22 (6.3)                          0.78 (0.40--1.54)                                                                        
  Log‐additive   ---          ---          ---                  .069                                               0.77 (0.59--1.02)                     
  rs1464890      Codominant   C/C          232 (48.1)           183 (52.3)                                         **.044**                1             **.925**
  T/C            197 (40.9)   140 (40.0)                        **0.68 (0.47--0.98)**                                                                    
  T/T            53 (11.0)    27 (7.7)                          0.55 (0.29--1.02)                                                                        
  Dominant       C/C          232 (48.1)   183 (52.3)           **.016**                                           1                       **.978**      
  T/C‐T/T        250 (51.9)   167 (47.7)                        **0.65 (0.46--0.93)**                                                                    
  Recessive      C/C‐T/C      429 (89.0)   323 (92.3)           .149                                               1                                     
  T/T            53 (11.0)    27 (7.7)                          0.65 (0.35--1.18)                                                                        
  Log‐additive   ---          ---          ---                  **.014**                                           0.72 (0.55--0.94)                     
  rs4507692      Codominant   C/C          233 (48.2)           183 (52.3)                                         **.049**                **1**         **.905**
  C/T            197 (40.8)   140 (40.0)                        **0.69 (0.48--0.99)**                                                                    
  T/T            53 (11.0)    27 (7.7)                          0.55 (0.29--1.03)                                                                        
  Dominant       C/C          233 (48.2)   183 (52.3)           **.019**                                           **1**                   **.969**      
  C/T‐T/T        250 (51.8)   167 (47.7)                        **0.66 (0.47--0.93)**                                                                    
  Recessive      C/C‐C/T      430 (89)     323 (92.3)           0.158                                              1                                     
  T/T            53 (11.0)    27 (7.7)                          0.65 (0.36--1.19)                                                                        
  Log‐additive   ---          ---          ---                  **.015**                                           **0.72 (0.55--0.94)**                 
  *SMARCA4*                                                                                                                                              
  rs11879293     Codominant   G/G          258 (53.4)           204 (58.3)                                         .110                    1              
  G/A            200 (41.4)   126 (36.0)                        0.68 (0.47--0.97)                                                                        
  A/A            25 (5.2)     20 (5.7)                          0.87 (0.41--1.81)                                                                        
  Dominant       G/G          258 (53.4)   204 (58.3)           **.044**                                           1                       **.898**      
  G/A‐A/A        225 (46.6)   146 (41.7)                        **0.70 (0.49--0.99)**                                                                    
  Recessive      G/G‐G/A      458 (94.8)   330 (94.3)           .960                                               1                                     
  A/A            25 (5.2)     20 (5.7)                          1.02 (0.49--2.09)                                                                        
  Log‐additive   ---          ---          ---                  .101                                               0.79 (0.59--1.05)                     
  rs12232780     Codominant   G/G          293 (60.7)           221 (63.1)                                         .210                    1              
  G/A            174 (36.0)   119 (34.0)                        0.72 (0.50--1.04)                                                                        
  A/A            16 (3.3)     10 (2.9)                          0.72 (0.26--2.00)                                                                        
  Dominant       G/G          293 (60.7)   221 (63.1)           .073                                               1                                     
  G/A‐A/A        190 (39.3)   129 (36.9)                        0.72 (0.51--1.03)                                                                        
  Recessive      G/G‐G/A      467 (96.7)   340 (97.1)           .678                                               1                                     
  A/A            16 (3.3)     10 (2.9)                          0.81 (0.30--2.22)                                                                        
  Log‐additive   ---          ---          ---                  .080                                               0.76 (0.55--1.04)                     
  rs1529729      Codominant   T/T          280 (58.2)           205 (58.6)                                         .772                    1              
  T/C            183 (38.0)   133 (38.0)                        0.98 (0.69--1.39)                                                                        
  C/C            18 (3.7)     12 (3.4)                          0.71 (0.28--1.80)                                                                        
  Dominant       T/T          280 (58.2)   205 (58.6)           .781                                               1                                     
  T/C‐C/C        201 (41.8)   145 (41.4)                        0.95 (0.67--1.34)                                                                        
  Recessive      T/T‐T/C      463 (96.3)   338 (96.6)           .469                                               1                                     
  C/C            18 (3.7)     12 (3.4)                          0.72 (0.28--1.80)                                                                        
  Log‐additive   ---          ---          ---                  .630                                               0.93 (0.69--1.25)                     
  rs1122608      Codominant   G/G          404 (83.6)           304 (86.9)                                         .081                    1              
  G/T            77 (15.9)    46 (13.1)                         0.63 (0.38--1.02)                                                                        
  T/T            2 (0.4)      0 (0.0)                           0.00 (0.00‐NA)                                                                           
  Dominant       G/G          404 (83.6)   304 (86.9)           **.047**                                           1                       **.846**      
  G/T‐T/T        79 (16.4)    46 (13.1)                         **0.61 (0.38--0.99)**                                                                    
  Recessive      G/G‐G/T      481 (99.6)   350 (100.0)          .252                                               1                                     
  T/T            2 (0.4)      0 (0.0)                           0.00 (0.00‐NA)                                                                           
  Log‐additive   ---          ---          ---                  **.038**                                           **0.61 (0.38--0.98)**                 

The bold values and *p \< *.05 indicate statistical significance.

Abbreviations: OR, odds ratio; SNP, single nucleotide polymorphism; 95% CI, 95% confidence interval.

*p* values were calculated by unconditional logistic regression analysis with adjustments for age and gender.
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3.4. Associations between haplotype analyses and hypertension risk {#mgg3942-sec-0015}
------------------------------------------------------------------

Linkage disequilibrium and haplotype analyses of the SNPs in the case and control samples were further studied. Haplotype analysis detected the block in *ZC3HC1* (Figure [1](#mgg3942-fig-0001){ref-type="fig"}). Rs2242487, rs1464890, and rs4507692 had very strong linkage disequilibria; compared to the "GCC" wild‐type, the haplotype ''ATT'' was associated with a decreased risk of hypertension (OR = 0.75; 95% CI = 0.56--0.99; *p* = .044) after adjustments for age and gender (Table [4](#mgg3942-tbl-0004){ref-type="table"}).

![Linkage disequilibrium (LD) plots containing four SNPs from *ZC3HC1*](MGG3-7-e942-g001){#mgg3942-fig-0001}

###### 

Haplotype analysis results in this study

  Haplotypes   Without adjusted   With adjusted                                                              
  ------------ ------------------ --------------- ------- ------------------- ------ ----------------------- ----------
  G            C                  C               0.701   1                   ---    1                       ---
  A            T                  T               0.253   0.83 (0.66--1.03)   .095   **0.75 (0.56--0.99)**   **.044**
  G            T                  T               0.045   0.94 (0.58--1.53)   .810   0.55 (0.29--1.02)       .056

The bold values and *p \< *.05 indicate statistical significance.

Abbreviations: CI, confidence interval; OR, odds ratio; SNP, single nucleotide polymorphism.

*p*: Adjusted by gender and age.
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4. DISCUSSION {#mgg3942-sec-0016}
=============

Genetic studies have provided insight into numerous diseases, including hypertension. Eight SNPs in *ZC3HC1* and *SMARCA4* have been investigated in other diseases. In this study, we examined 833 subjects (350 patients with hypertension and 483 healthy controls) to determine whether they were associated with the risk of hypertension in the Han Chinese population. Our results suggest that rs1464890 and rs4507692 (*ZC3HC1*), rs11879293 (*SMARCA4*) and rs1122608 (*SMARCA4*) were conducive to play a protective role to against the risk of hypertension. In addition, the "ATT" *ZC3HC1* haplotype was associated with a 0.75‐fold decreased risk of hypertension.

*ZC3HC1* (zinc finger, C3HC‐type containing 1) was also called NIPA (nuclear interaction partner of ALK), which could monitor the timing of mitotic entry and was thought to contribute to the development of carcinogenesis together with oncogenic proteins (Li & Morris, [2008](#mgg3942-bib-0012){ref-type="ref"}). Studies have been shown that mediators of angiogenesis may play an important role in the regulation of endothelial integrity and inflammation and it was possible that changes in the stability and functional properties of *ZC3HC1* protein may play a role in the endothelial dysfunction (Schunkert et al., [2011](#mgg3942-bib-0023){ref-type="ref"}), especially in the coronary heart disease and hypertension. Recently, a genome‐wide association study, reported by Linseman et al. ([2017](#mgg3942-bib-0013){ref-type="ref"}), found that *ZC3HC1* polymorphism was associated with a protective role in coronary artery disease. Kunnas and Nikkari ([2015](#mgg3942-bib-0010){ref-type="ref"}) reported the association of *ZC3HC1* rs11556924 genetic variant with hypertension in a Finnish population. However, in previous studies, many reports only focused on the association of genetic variant in *ZC3HC1* (rs11556924) with diseases, the genetic polymorphism of other locus in *ZC3HC1* were little reported. Therefore, in our research, we studied the relationship between *ZC3HC1* SNPs (rs2242487, rs1464890, and rs4507892) and hypertension in Chinese Han population, and we found that the polymorphism of *ZC3HC1* (rs1464890) has a strong protective effects on the hypertension.

*SMARCA4* (also known as *BRG1*) is located in chromosomal region of 19p13.2, and its protein is the important catalytic component of the SWI/SNF complexes (Moes‐Sosnowska et al., [2015](#mgg3942-bib-0018){ref-type="ref"}). It is composed of multiple domains, a conserved C‐terminal bromodomain, the less characterized N‐terminal region which has crucial effect on DNA binding, recruitment of SWI/SNF, and the recognition of modified histone proteins (Singh, D\'Silva, & Holak, [2006](#mgg3942-bib-0025){ref-type="ref"}). *SMRACA4* is located closely to the low‐density lipoprotein receptor gene and disrupting chromatin structure regulates the transcription of various genes using the chemical energy of adenosine triphosphate hydrolysis (Mulholland, Xu, Sugiyama, & Zhao, [2012](#mgg3942-bib-0020){ref-type="ref"}). In our research, we found rs11879293 and rs1122608 in *SMARCA4* seemed to have strong protective effects on the hypertension. However, the previous studies, Guo et al. ([2017](#mgg3942-bib-0006){ref-type="ref"}) found rs11879293 was associated with decreasing the risk of coronary heart disease, and another study found rs11879293 was associated with increasing the risk of hepatocellular carcinoma is more pronounced in males, younger individuals, and nondrinkers (Pan et al., [2007](#mgg3942-bib-0021){ref-type="ref"}). Kathiresan, Willer, et al. ([2009](#mgg3942-bib-0008){ref-type="ref"}) found the loci rs1122608 was associated with elevating the risk of low‐density lipoprotein cholesterol and coronary heart disease in Caucasian population. At present, there were no relevant reports on the relationship between rs11879293 and rs1122608 with hypertension. Therefore, in future studies, we will consider that the *SMARCA4* may function differently in varying disease mechanisms.

To sum up, in our study, we confirmed two genes (*ZC3HC1* and *SMARCA4*) are associated with risk of hypertension in Han Chinese population for the first time, which may provide new data to facilitate earlier diagnosis and promote early prevention, and shed light on the new candidate genes and new ideas for the study of subsequent occurrence mechanism of hypertension. Some potential limitations of our current study should be considered when interpreting the results. Investigating these SNPs should use more clinical data with bigger samples. Our current research is fundamental; further functional studies and larger population‐based prospective studies are required to understand the genetic factors underlying hypertension.
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